Cargando…

Are There Still Difficult-to-Treat Patients with Chronic Hepatitis C in the Era of Direct-Acting Antivirals?

Difficult-to-treat populations with chronic hepatitis C (CHC), in the era of interferon treatment, included patients with liver cirrhosis, kidney impairment, treatment-experienced individuals, and those coinfected with the human immunodeficiency virus. The current study aimed to determine whether, i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pabjan, Paweł, Brzdęk, Michał, Chrapek, Magdalena, Dziedzic, Kacper, Dobrowolska, Krystyna, Paluch, Katarzyna, Garbat, Anna, Błoniarczyk, Piotr, Reczko, Katarzyna, Stępień, Piotr, Zarębska-Michaluk, Dorota
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8779728/ https://www.ncbi.nlm.nih.gov/pubmed/35062302 http://dx.doi.org/10.3390/v14010096

Ejemplares similares

Retreatment of symptomatic hepatitis C virus genotype 3 associated mixed cryoglobulinemia with sofosbuvir and ribavirin: a case report
por: Zarębska-Michaluk, Dorota, et al.
Publicado: (2018)

Predictors of sustained virological response in patients with hepatitis C virus genotype 3 infection
por: Zarębska-Michaluk, Dorota, et al.
Publicado: (2016)

Severe intrahepatic cholestasis and liver failure after stanozolol usage – case report and review of the literature
por: Stępień, Piotr M., et al.
Publicado: (2015)

Decade of optimizing therapy with direct-acting antiviral drugs and the changing profile of patients with chronic hepatitis C
por: Brzdęk, Michał, et al.
Publicado: (2023)

Megamitochondria formation in hepatocytes of patient with chronic hepatitis C – a case report
por: Wieczorek, Anna, et al.
Publicado: (2017)

Retrospective Analysis of the Effectiveness of Remdesivir in COVID-19 Treatment during Periods Dominated by Delta and Omicron SARS-CoV-2 Variants in Clinical Settings
por: Dobrowolska, Krystyna, et al.
Publicado: (2023)

COVID-19 Vaccine Booster Strategies for Omicron SARS-CoV-2 Variant: Effectiveness and Future Prospects
por: Zarębska-Michaluk, Dorota, et al.
Publicado: (2022)

Global Elimination of HCV—Why Is Poland Still So Far from the Goal?
por: Tronina, Olga, et al.
Publicado: (2023)

Early oral antiviral use in patients hospitalised with COVID-19
por: Zarębska-Michaluk, Dorota, et al.
Publicado: (2022)

Change in the Clinical Picture of Hospitalized Patients with COVID-19 between the Early and Late Period of Dominance of the Omicron SARS-CoV-2 Variant
por: Flisiak, Robert, et al.
Publicado: (2023)

Variability in the Clinical Course of COVID-19 in a Retrospective Analysis of a Large Real-World Database
por: Flisiak, Robert, et al.
Publicado: (2023)

Changes in characteristics of patients with hepatitis C virus-related cirrhosis from the beginning of the interferon-free era
por: Brzdęk, Michał, et al.
Publicado: (2023)

Real-world effectiveness and safety of direct-acting antivirals in hepatitis C virus patients with mental disorders
por: Dybowska, Dorota, et al.
Publicado: (2023)

Real-World Efficacy and Safety of an 8-Week Glecaprevir/Pibrentasvir Regimen in Children and Adolescents with Chronic Hepatitis C—Results of a Multicenter EpiTer-2 Study
por: Pawlowska, Malgorzata, et al.
Publicado: (2023)

Pangenotypic triple versus double therapy in HCV-infected patients after prior failure of direct-acting antivirals
por: Flisiak, Robert, et al.
Publicado: (2023)

Rescue Therapy after Failure of HCV Antiviral Treatment with Interferon-Free Regimens
por: Tronina, Olga, et al.
Publicado: (2023)

Updates in Management of SARS-CoV-2 Infection
por: Flisiak, Robert, et al.
Publicado: (2022)

Reduced Vessel Density and Enlarged Foveal Avascular Zone in the Macula as a Result of Systemic Hypoxia Caused by SARS-CoV-2 Infection
por: Kal, Magdalena, et al.
Publicado: (2023)

Pangenotypic and Genotype-Specific Antivirals in the Treatment of HCV Genotype 4 Infected Patients with HCV Monoinfection and HIV/HCV Coinfection
por: Zarębska-Michaluk, Dorota, et al.
Publicado: (2022)

Viral hepatitis C treatment shortening – what is the limit?
por: Zarębska-Michaluk, Dorota
Publicado: (2019)

Genotype 3-hepatitis C virus’ last line of defense
por: Zarębska-Michaluk, Dorota
Publicado: (2021)

The Course of COVID-19 in Patients with Systemic Autoimmune Rheumatic Diseases
por: Rorat, Marta, et al.
Publicado: (2022)

The Effect of Reduced Oxygen Saturation on Retinal Microvascularization in COVID-19 Patients with Bilateral Pneumonia Based on Optical Coherence Tomography Study
por: Kal, Magdalena, et al.
Publicado: (2022)

Real-world experience with molnupiravir during the period of SARS-CoV-2 Omicron variant dominance
por: Flisiak, Robert, et al.
Publicado: (2022)

Correction: Real-world experience with molnupiravir during the period of SARS-CoV-2 Omicron variant dominance
por: Flisiak, Robert, et al.
Publicado: (2022)

Impact of Kidney Failure on the Severity of COVID-19
por: Zarębska-Michaluk, Dorota, et al.
Publicado: (2021)

Severe Breakthrough COVID-19 Cases during Six Months of Delta Variant (B.1.617.2) Domination in Poland
por: Rzymski, Piotr, et al.
Publicado: (2022)

Long-Term Effect of SARS-CoV-2 Infection on the Retinal and Choroidal Microvasculature
por: Kal, Magdalena, et al.
Publicado: (2023)

Does Hospitalization Change the Perception of COVID-19 Vaccines among Unvaccinated Patients?
por: Zarębska-Michaluk, Dorota, et al.
Publicado: (2022)

Trends of infections and mortality due to hepatitis B virus (2005-2022) and the potential impact of the COVID-19 pandemic: a population-based study in Poland
por: Genowska, Agnieszka, et al.
Publicado: (2023)

Perspectives of hepatitis C virus (HCV) elimination in Poland
por: Flisiak, Robert, et al.
Publicado: (2019)

Obligation Is Not a Compulsion—The Quality of the Law and the Effectiveness and Safety of Vaccination against COVID-19
por: Kocańda, Kamila, et al.
Publicado: (2022)

Oral antiviral treatments for COVID-19: opportunities and challenges
por: Rahmah, Laila, et al.
Publicado: (2022)

Correction: Oral antiviral treatments for COVID-19: opportunities and challenges
por: Rahmah, Laila, et al.
Publicado: (2022)

Effectiveness and Safety of Pangenotypic Regimens in the Most Difficult to Treat Population of Genotype 3 HCV Infected Cirrhotics
por: Zarębska-Michaluk, Dorota, et al.
Publicado: (2021)

Retinal Microvascular Changes in COVID-19 Bilateral Pneumonia Based on Optical Coherence Tomography Angiography
por: Kal, Magdalena, et al.
Publicado: (2022)

The Levels of Anti-SARS-CoV-2 Spike Protein IgG Antibodies Before and After the Third Dose of Vaccination Against COVID-19
por: Łysek-Gładysińska, Małgorzata, et al.
Publicado: (2023)

Metrological Evaluation of the Demosaicking Effect on Colour Digital Image Correlation with Application in Monitoring of Paintings
por: Papanikolaou, Athanasia, et al.
Publicado: (2022)

Clostridium difficile phages: still difficult?
por: Hargreaves, Katherine R., et al.
Publicado: (2014)

Ways to Eliminate Viral Hepatitis as a Global Health Threat
por: Flisiak, Robert, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_h5dk655ramt90knb599vo7kpsp